Molecular Characterization and Clinical Relevance of MGMT-Silenced Pancreatic Cancer.

Prognostic Impact of MGMT Silencing in PAC MGMT ‐methylated PAC patients had a nonsignificant trend toward longer overall survival (OS, 21.7 vs. 19.5 months, HR 0.72 [95%CI 0.39–1.32], Wald test p = 0.26), which was confirmed using MGMT expression values (as a continuous variable) in a univariable and multivariable analysis (Figure 3a,b and Figure S9a,b ). 3.6.

also in 5,406 other papers